Read here for an analysis of LifeVantage's (LFVN) stock surge post GLP-1 trial, cautioning on pricing, retention, and ...

People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 ...

E arlier this month, Kourtney Kardashian’s supplement brand, Lemme, joined the growing market for Ozempic dupes with the ...

Employers that cover GLP-1s are partnering with vendors to design benefits and manage lifestyle programs, but the "jury is ...

In an interview with Peers & Perspectives in Oncology, Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

A study highlights that GLP-1 RAs are linked to a reduced risk of cirrhosis in patients with MASLD and diabetes. Learn more ...

About 40% of U.S. adults suffer from obesity, and the cost of covering GLP-1 agonists and related anti-obesity drugs can be ...

Semaglutide (Ozempic, Wegovy) may help reduce the risk of an opioid overdose in certain people, an emulation target trial ...

Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...

The demand for weight loss medications are on the rise, and now, “natural” GLP-1s are being marketed to help you lose weight.